Absolute numbers of CFUs formed at day 7 following treatment with retinoids
. | . | . | Genotype . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ligand . | RAR selectivity . | Type . | Wild-type . | p27Kip1-/- . | Mad1-/- . | Mad1-/-p27Kip1-/- . | RARα-/- . | RARγ-/- . | |||||
| Ethanol | — | — | 99.7 ± 2.7 | 128.3 ± 8.0 | 86.8 ± 3.8 | 128.1 ± 7.2 | 92.8 ± 2.9 | 95.9 ± 3.9 | |||||
| ATRA | α,β,γ | Agonist | 47.3 ± 3.8* | 56.8 ± 7.1* | 44.8 ± 5.6* | 54.4 ± 3.7* | 57.6 ± 5.8* | 42.0 ± 1.5* | |||||
| AGN194310 | α,β,γ | Antagonist | 93.6 ± 3.0 | 127.4 ± 7.8 | 105.0 ± 8.9† | 118.9 ± 5.8 | 90.2 ± 2.6 | 85.8 ± 8.7 | |||||
| AGN195183 | α | Agonist | 56.4 ± 1.9* | 75.3 ± 5.0* | 53.0 ± 6.8* | 113.8 ± 7.4 | 88.9 ± 4.0 | 56.8 ± 2.6* | |||||
| AGN194078 | α | Agonist | 63.0 ± 2.7* | 84.1 ± 7.9* | 60.2 ± 3.2* | 120.3 ± 7.8 | ND | ND | |||||
| ATRA + AGN194301 | β,γ | Agonist | 44.3 ± 5.6* | 54.8 ± 3.1* | 43.9 ± 3.8* | 56.6 ± 4.9* | 47.3 ± 1.8*‡ | 85.5 ± 5.7 | |||||
| AGN194301 | α | Antagonist | 92.5 ± 2.9 | 118.0 ± 3.0 | 87.6 ± 4.1 | 115.6 ± 6.5 | 105.5 ± 3.7‡ | 94.8 ± 4.2 | |||||
. | . | . | Genotype . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ligand . | RAR selectivity . | Type . | Wild-type . | p27Kip1-/- . | Mad1-/- . | Mad1-/-p27Kip1-/- . | RARα-/- . | RARγ-/- . | |||||
| Ethanol | — | — | 99.7 ± 2.7 | 128.3 ± 8.0 | 86.8 ± 3.8 | 128.1 ± 7.2 | 92.8 ± 2.9 | 95.9 ± 3.9 | |||||
| ATRA | α,β,γ | Agonist | 47.3 ± 3.8* | 56.8 ± 7.1* | 44.8 ± 5.6* | 54.4 ± 3.7* | 57.6 ± 5.8* | 42.0 ± 1.5* | |||||
| AGN194310 | α,β,γ | Antagonist | 93.6 ± 3.0 | 127.4 ± 7.8 | 105.0 ± 8.9† | 118.9 ± 5.8 | 90.2 ± 2.6 | 85.8 ± 8.7 | |||||
| AGN195183 | α | Agonist | 56.4 ± 1.9* | 75.3 ± 5.0* | 53.0 ± 6.8* | 113.8 ± 7.4 | 88.9 ± 4.0 | 56.8 ± 2.6* | |||||
| AGN194078 | α | Agonist | 63.0 ± 2.7* | 84.1 ± 7.9* | 60.2 ± 3.2* | 120.3 ± 7.8 | ND | ND | |||||
| ATRA + AGN194301 | β,γ | Agonist | 44.3 ± 5.6* | 54.8 ± 3.1* | 43.9 ± 3.8* | 56.6 ± 4.9* | 47.3 ± 1.8*‡ | 85.5 ± 5.7 | |||||
| AGN194301 | α | Antagonist | 92.5 ± 2.9 | 118.0 ± 3.0 | 87.6 ± 4.1 | 115.6 ± 6.5 | 105.5 ± 3.7‡ | 94.8 ± 4.2 | |||||
CFUs include mixed, erythroid, granulocyte-macrophage, granulocyte, and megakaryocyte CFUs.
Methylcellulose CFU assays were performed using 50 000 whole bone marrow cells/mL in 3% methylcellulose, fetal calf serum, IL-6, IL-3, SCF, and erythropoietin.
Results are expressed as mean ± SEM, with 4 mice or more of each genotype (‡n = 3). All assays were performed in duplicate.
— indicates control; and ND, not determined.
P < .003 relative to ethanol control for given genotype.
P < .05 relative to ethanol control for given genotype.